Prothrombin fragments F1+2, thrombin-antithrombin III complexes, fibrin monomers and fibrinogen in patients with coronary atherosclerosis. 1999

E Giannitsis, and H J Siemens, and R Mitusch, and I Tettenborn, and U Wiegand, and G Schmücker, and A Sheikhzadeh, and U Stierle
Medical Department II, Medical University of Lübeck, Germany.

We determined the plasma levels of prothrombin fragment F1+2, thrombin-antithrombin III complexes (TAT), fibrin monomers (FM), D-dimers (DD) and fibrinogen in 57 patients with angiographically verified graded coronary artery disease (CAD) free of concomitant peripheral atherosclerosis, cerebrovascular disease or diabetes mellitus and a group of 21 apparently healthy controls. Blood was collected from the antecubital vein through atraumatic venipuncture prior to the angiographic procedure. Plasma levels of hemostatic markers were related to the presence and graded severity of CAD. The levels of prothrombin fragment F1+2 (1.74+/-0.11 vs. 1.0+/-0.07 nmol/l, P<0.001), FM (41.6+/-5.5 vs. 7.42+/-3.05 nmol/l, P<0.001), TAT (15.6+/-2.7 vs. 2.96+/-0.32 microg/l, P<0.001) and fibrinogen (3.64+/-1.3 vs. 3.08+/-0.33 g/l, P<0.01) were significantly higher in patients with CAD compared to controls, while there was no difference regarding the fibrinolytic system represented by DD (441.6+/-58.9 vs. 337.4+/-42.05 microg/l, n.s.). Within the CAD group, patients with extensive coronary atherosclerosis (> or =2 vessel disease) had significantly higher values for prothrombin fragment F1+2 (1.89 vs. 1.57 nmol/l, P = 0.04), FM (50.7 vs. 29.8 nmol/l, P = 0.03), and a trend to significance was noted for fibrinogen (3.9 vs. 3.3 g/l, P = 0.07) suggesting that blood coagulability was related to the severity of the disease and that hemostatic markers of thrombin activity represent a useful tool to identify patients with a latent hypercoagulable state with a higher susceptibility to sustain coronary thrombosis.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010447 Peptide Hydrolases Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES. Peptidase,Peptidases,Peptide Hydrolase,Protease,Proteases,Proteinase,Proteinases,Proteolytic Enzyme,Proteolytic Enzymes,Esteroproteases,Enzyme, Proteolytic,Hydrolase, Peptide
D011516 Prothrombin A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia. Coagulation Factor II,Factor II,Blood Coagulation Factor II,Differentiation Reversal Factor,Factor II, Coagulation,Factor, Differentiation Reversal,II, Coagulation Factor
D003324 Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause. Arteriosclerosis, Coronary,Atherosclerosis, Coronary,Coronary Arteriosclerosis,Coronary Atherosclerosis,Left Main Coronary Artery Disease,Left Main Coronary Disease,Left Main Disease,Arterioscleroses, Coronary,Artery Disease, Coronary,Artery Diseases, Coronary,Atheroscleroses, Coronary,Coronary Arterioscleroses,Coronary Artery Diseases,Coronary Atheroscleroses,Left Main Diseases
D005260 Female Females
D005338 Fibrin Fibrinogen Degradation Products Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis. Antithrombin VI,Fibrin Degradation Product,Fibrin Degradation Products,Fibrin Fibrinogen Split Products,Degradation Product, Fibrin,Degradation Products, Fibrin,Product, Fibrin Degradation
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D006487 Hemostasis The process which spontaneously arrests the flow of BLOOD from vessels carrying blood under pressure. It is accomplished by contraction of the vessels, adhesion and aggregation of formed blood elements (eg. ERYTHROCYTE AGGREGATION), and the process of BLOOD COAGULATION. Hemostases

Related Publications

E Giannitsis, and H J Siemens, and R Mitusch, and I Tettenborn, and U Wiegand, and G Schmücker, and A Sheikhzadeh, and U Stierle
July 1998, Thrombosis research,
E Giannitsis, and H J Siemens, and R Mitusch, and I Tettenborn, and U Wiegand, and G Schmücker, and A Sheikhzadeh, and U Stierle
August 1992, Sangre,
E Giannitsis, and H J Siemens, and R Mitusch, and I Tettenborn, and U Wiegand, and G Schmücker, and A Sheikhzadeh, and U Stierle
August 2002, Medical science monitor : international medical journal of experimental and clinical research,
E Giannitsis, and H J Siemens, and R Mitusch, and I Tettenborn, and U Wiegand, and G Schmücker, and A Sheikhzadeh, and U Stierle
June 2004, Zeitschrift fur Geburtshilfe und Neonatologie,
E Giannitsis, and H J Siemens, and R Mitusch, and I Tettenborn, and U Wiegand, and G Schmücker, and A Sheikhzadeh, and U Stierle
January 2000, Przeglad lekarski,
E Giannitsis, and H J Siemens, and R Mitusch, and I Tettenborn, and U Wiegand, and G Schmücker, and A Sheikhzadeh, and U Stierle
May 1996, Gynecologic oncology,
E Giannitsis, and H J Siemens, and R Mitusch, and I Tettenborn, and U Wiegand, and G Schmücker, and A Sheikhzadeh, and U Stierle
October 1993, Thrombosis and haemostasis,
E Giannitsis, and H J Siemens, and R Mitusch, and I Tettenborn, and U Wiegand, and G Schmücker, and A Sheikhzadeh, and U Stierle
January 1991, Thrombosis and haemostasis,
E Giannitsis, and H J Siemens, and R Mitusch, and I Tettenborn, and U Wiegand, and G Schmücker, and A Sheikhzadeh, and U Stierle
January 1996, Polish journal of pharmacology,
E Giannitsis, and H J Siemens, and R Mitusch, and I Tettenborn, and U Wiegand, and G Schmücker, and A Sheikhzadeh, and U Stierle
February 2020, Thrombosis research,
Copied contents to your clipboard!